Kornimate/medical-research-clean huggingface dataset:
abridge ai pilot test

Conditions: Clinician Experience; Clinician Burnout

Summary: we are piloting a new technology (abridge) that uses artificial intelligence to listen to clinician-patient office visits and then document the interaction in the electronic health record.

this study will evaluate pilot implementation of the abridge artificial intelligence (ai) platform (abridge) in uchealth clinics. abridge licenses will be deployed to 116 physician and advanced practice clinicians to accomplish the following goals: 1. determine if abridge meaningfully impacts clinician documentation time and burnout or stress 2. determine whether to scale abridge beyond the pilot we will evaluate clinician experiences using abridge, particularly with regard to documentation time and clinician burnout or stress. study findings will explore value added in integrating abridge into clinician practice, and guide decision-making for entering into a commercial agreement with abridge. this pilot will also inform best practices for scaling abridge to a broader user base across uchealth outpatient practices.

Eligibility criteria:
inclusion criteria: -clinician (physician, advance practice professional, or licensed mental health professional) employed by uchealth * see clinic patients at least three half-day sessions per week. (half-day sessions seeing or supervising patients with residents and fellows will not count toward the weekly total. half-day sessions seeing patients with a medical student can count toward the weekly total, however, abridge can only capture conversations where you are physically present with patients.) * own an ios smartphone and be willing to download and use the epic haiku smartphone app during clinic visits exclusion criteria: * trainees including residents and fellows * pt/ot, ed, maternal/fetal, pediatric, dental, eye specialties

Keywords: ambient ai clinician burnout
dsuvia early evaluation of pain trial

Conditions: Traumatic Injury

Summary: randomized, interventional trial of emergency department (ed) administration of dsuvia (sufentanil) versus standard care pain management comparing pain treatment outcomes in injured patients with moderate to severe pain


Eligibility criteria:
inclusion criteria: 1. trauma activation (level i, ii or iii) 2. age 18-70 years inclusive 3. need for pain treatment based upon nrs (0-100) clinical pain measurement ≥ 50 4. estimated time in emergency department \> 30 minutes following informed consent exclusion criteria: 1. advanced airway management prior to 1st dose administration 2. known allergy to opioids 3. known prisoner 4. known pregnancy 5. ed pain medication contraindicated 6. significant respiratory depression 7. known or suspected gastrointestinal obstruction, including paralytic ileus
intravitreal avastin in proliferative retinopathies

Conditions: Retinal Neovascularization

Summary: the study intends to assess the effect of avastin injections in different proliferative retinopathies due to different causes

proliferative retinopathies due to different causes represent important causes for the visual acuity loss. conventional treatments may sometimes improve the visual function, whereas other times, the visual acuity continue to decrease, in spite of all the medical, surgical or laser treatments. intravitreal injections with anti-vegf agents (ex. avastin for our trial) seem to be an important tool for certain difficult situations in which at the ocular fundus, out of different reasons (advanced age, diabetes mellitus, retinal veins occlusions, etc)new pathologic vessels appear, causing devastating changes in the posterior and anterior segment as well.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of a proliferative retinopathy (age related macular degeneration,diabetic proliferative retinopathy, etc) * distance acuity \< 0.5 * age \> 20 years exclusion criteria: * noncooperative patients * ocular infections / inflammations

Keywords: antivegf therapy
validation of venogenic hypothesis for cough, exertional and sexual headaches

Conditions: Headache

Summary: clinical and neuroradiologic study concerning patients suffering of cough, exertional and sexual headaches disorders (pathophysiology) concerning a venous hypothesis implication, redescribe clinical headaches specifications, confirmed if cough headaches is a clinical entity and if it has neuroradiologic differences with effort or sexual activity headaches.


Eligibility criteria:
inclusion criteria: * patients suffering of headache disorders exclusion criteria: * none

Keywords: headache
a study of laparoscopic hepatectomy versus rfa in the treatment of recurrent hcc

Conditions: Hepatocellular Carcinoma Recurrent

Summary: to observe and compare the short-term and long-term oncological outcome of laparoscopic hepatectomy and radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma .

background \& aims: hepatocellular carcinoma (hcc) is the third leading cause of cancer-related death in the world. the 5-year recurrent rate of hcc after first curative resection is 77%\~100%. laparoscopic repeat liver resection (lrlr) has been shown in small retrospective studies to be a safe and effective treatment for recurrent hepatocellular carcinoma (rhcc) in selected patients, and radiofrequency ablation (rfa) has been increasingly performed for treating recurrent tumors involving the liver after hepatectomy. the aim of this study was to compare the short-term and long-term outcome of laparoscopic hepatectomy (lh) and radiofrequency ablation (rfa) in the treatment of rhcc.

Eligibility criteria:
inclusion criteria: * any gender,18 to 70 years old; * preoperative diagnosis of recurrent hcc clear,liver resection was done previously; * no active hepatitis and decompensated cirrhosis; * patient with previous liver resection, maximum diameter ≤5cm single recurrent nodules or 3 nodules in diameter and no more than 3cm,did not infringe the portal vein,hepatic vein and inferior vena cava invasion,lymph node or extrahepatic turn; * no tumor rupture or bleeding; * child-pugh class a or b grade,icg-r15 \<20%; * no coagulation disorders,platelet count \> 50 × 109 / l and prolonged prothrombin time \< 5 seconds; * after diagnosis of recurrent hcc,not be including related surgery,radiofrequency ablation (rfa),tace treatment,no certainty anticancer chemotherapy treatment;supreme absolute contraindications abdominal surgery; * recurrent nodules are not close to intestines,stomach,cholecyst or diaphragm muscle, not close to the first porta hepatis,main vessel and biliary ducts; * patients generally available,heart and lung function can tolerate surgery, abdominal surgery supreme absolute contraindications; * voluntarily participate in the study, voluntarily accept any therapy of two,informed consent. exclusion criteria: * opposite of the above inclusion criteria; * severe upper abdominal adhesions; * postoperative pathological examination of the bile duct cell or mixed cell carcinoma and pathologically confirmed positive margin; * foreign,hong kong,macao,taiwan and other regions,estimated postoperative difficult to track,followed up; * nodules proved to be not recurrent hcc during intraoperative exploration, such as:liver metastases of colorectal cancer.

Keywords: recurrent hcc laparoscopic hepatectomy rfa rct
comparing the difference in pain control in the pediatric general surgery population: to alternate or combine acetaminophen and ibuprofen?

Conditions: Pediatric Disorder

Summary: to examine the difference in pain control in the pediatric general surgery population alternating acetaminophen and ibuprofen q 3 hours vs giving them simultaneous combination therapy around the clock.

the purpose of the study is to compare the difference in pain control in the pediatric general surgery population of those who receive alternating acetaminophen and ibuprofen every 3 hours to those who receive acetaminophen and ibuprofen combined therapy around the clock. additionally, to investigate the difference in parent adherence to pain treatment plans between the alternating group from the combined group.

Eligibility criteria:
inclusion criteria: * age group: 3 years to 18 years * general surgery service (hernia, appendectomy, chole, circumcision, wounds, vacs, implanted central line, etc.) exclusion criteria: * patients who are allergic to acetaminophen and/or ibuprofen * patients being evaluated by sane or evaluated for nonaccidental trauma * patients admitted post-op the study will take place at mclane children's hospital temple market. patients who are pregnant.

Keywords: non opioid pain management pediatric pain pediatric pain management
autologous platelet rich plasma intraovarian infusion for poor responders

Conditions: Poor Response to Ovulation Induction; Infertility, Female; Ovarian Insufficiency; Ovarian Failure; Reproductive Sterility; Ovary; Anomaly

Summary: autologous platelet rich plasma (prp) intraovarian infusion may improve ovarian response to controlled ovarian stimulation as well as the hormonal profile of poor ovarian response infertile women subjected to intracytoplasmic sperm injection (icsi) treatment.

despite recent advances in reproductive medicine, poor ovarian response (por) management is still considered to be very challenging. commonly, por patients present with reduced ovarian reserve and poor ovarian stimulation performance. the por cycles are characterized by a very limited number of retrieved oocytes, subsequently leading to poor embryo formation and thus to high cycle cancelation rate. despite the fact that por constitutes a multifactorial condition, it is well demonstrated that advanced maternal age (ama) is the most significant contributor of por. as maternal age increases, reduction of neo-angiogenesis in ovaries is observed, leading to accelerated follicular loss. considering that prp contains several growth factors such as vascular endothelial growth factor (vegf) and cytokines, it has been proposed that intraovarian infusion of autologous prp could restore the ovarian niche microenvironment, increasing ovarian response to external gonadotropin stimulation. however, limited data are available with regards to prp efficiency in por patients, which are mainly originating from pilot or small cohort studies. this interventional non-randomised open-label study aims to investigate the effect of autologous prp intraovarian infusion on improving por patient performance by studying a large and well-controlled por population.

Eligibility criteria:
inclusion criteria: poor ovarian response according to bologna criteria (fulfilling 2 out of 3 of the following): 1. age ≥ 40 years 2. amh \< 1.1 ng/ml or afc \< 7 3. ≤ 3 oocytes with a conventional stimulation protocol * discontinuation of any complementary/adjuvant treatment including hormone replacement and acupuncture, for at least three months prior to recruitment. * willing to comply with study requirements exclusion criteria: * any pathological disorder related to reproductive system anatomy * cycle irregularities * amenorrhea * endometriosis * adenomyosis * fibroids and adhesions * infections in reproductive system * current or previous diagnosis of cancer in reproductive system * history of familiar cancer in reproductive system * severe male factor infertility * prior referral for preimplantation genetic testing (pgt) -ovarian inaccessibility -endocrinological disorders (hypothalamus- * pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome) * bmi\>30 kg/m2 or bmi\<18.5 kg/m2 * systematic autoimmune disorders

Keywords: autologous platelet rich plasma intraovarian infusion assisted reproduction prp in vitro fertilization ovarian functionality improvement
effect of mechanical interface mobilization technique on pain and functional status in carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: the aim of this study is to find out the influence of mechanical interface mobilization technique which consists of 5 different steps, in management of carpal tunnel syndrome and how this technique effects pain and functional status in individuals who has carpal tunnel syndrome.

the median nerve gets entrapped in the wrist, causing carpal tunnel syndrome (cts), the most prevalent peripheral neuropathy in the upper limb. a number of clinical findings, such as sensory issues with the first three digits of the hand sensory distribution of the median nerve, a positive phalen test, weakness and atrophy of the thenar muscle, and electrophysiological findings (prolonged motor and sensory distal latencies of the median nerve) are used to diagnose cts . the most frequent occupational risk factors for cts are repetitive wrist and finger motions or holding uncomfortable wrist positions for extended periods of time. tenosynovitis of the finger flexors, a thicker transverse carpal ligament, a fracture or dislocation of the distal radius or lunate, rheumatoid arthritis, lipoma, diabetes, and hyperthyroidism are other non-occupational causes . a combination of techniques has been used in the studies of seradge h. et al and sucher benjamin m. et al which included mechanical interface and neuro-dynamics, but the isolated effects of each method is yet to be determined by further studies as their combined effects are more focused on in the current literature. and that leads to an unclear decision about, which group of manual therapy techniques has better effects on individuals suffering from cts .

Eligibility criteria:
inclusion criteria: * positive phalen test and tinel test. * positive symptoms of cts (pain, numbness, or tingling in the first three and lateral half of the fourth finger. exclusion criteria: * no previous surgical treatments at the wrist joint, no fractures or open wounds at the wrist. * patients with thoracic outlet syndrome, and cervical radiculopathy. * history of carpal tunnel release surgery. * steroid injection in the carpal tunnel. * pregnant females. * metabolic diseases such as diabetes, severe thyroid disorders and anemia.

Keywords: cts
a trial of rsc-1255 for treatment of patients with advanced malignancies

Conditions: Advanced Malignant Solid Neoplasm; RAS Mutation; Lung Cancer; Colon Cancer; Glioblastoma; Pancreatic Cancer

Summary: rsc-101 is a phase 1a/1b clinical trial of rsc-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. the study has two phases. the purpose of phase 1a (dose escalation) is to confirm the appropriate treatment dose and phase 1b (dose expansion) is to characterize the safety and efficacy of rsc-1255.

rsc-1255 is an orally bioavailable, small-molecule direct pan-mutant and wild-type ras inhibitor. rsc-101 is a phase 1a/1b, open-label, multi-center, non-randomized, dose escalation and dose expansion study in participants with advanced solid tumor malignancies. study enrollment is approximately 134 participants. all participants receive oral rsc-1255, twice daily as monotherapy. following phase 1a (dose escalation) to identify the maximum tolerated dose and recommended dose for use in phase 1b, additional participants are enrolled in the phase 1b (dose expansion) to further characterize the safety, pharmacology, and the clinical efficacy of rsc-1255.

Eligibility criteria:
inclusion criteria (key factors): 1. has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following: * participant is intolerant of existing therapy(ies) known to provide clinical benefit for their condition * malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit * malignancy has progressed on standard therapy 2. has evaluable or measurable tumor(s) in dose-escalation by standard radiological and/or laboratory assessments as applicable to their malignancy. 3. has adequate performance status (ps): eastern co-operative oncology group (ecog). 4. is age ≥ 18 years. exclusion criteria (key factors): 1. participants receiving cancer therapy at the time of enrollment. 2. any clinically significant disease or condition affecting a major organ system. 3. significant cardiovascular disease or electrocardiogram (ecg) abnormalities. 4. known gilbert's disease. 5. has had a previous (within 2 years) or has a current malignancy other than the target cancer.

Keywords: malignancy cancer refractory ras mutation lung colon glioblastoma rsc-1255 progression pancreatic
radicle calm 1: a study of health and wellness products on feelings of anxiety, stress and other health outcomes

Conditions: Anxiety; Stress

Summary: a randomized, blinded, placebo-controlled, direct-to-consumer study assessing the impact of health and wellness products on feelings of anxiety, stress and other health outcomes

this is a randomized, blinded, placebo-controlled study conducted with up to 300 adult participants per study arm, age 21 and older and residing in the united states. eligible participants will (1) endorse a desire for less feelings of anxiety and/or stress, (2) indicate an interest in taking a health and wellness product to potentially improve their anxiety and/or stress, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study. participants with known liver or kidney disease, heavy drinkers, and those who are pregnant, trying to become pregnant, or breastfeeding will be excluded. those taking certain medications will be excluded. self-reported data will be collected electronically from eligible participants over 5 weeks. participant reports of health indicators will be collected during baseline, throughout the active period of study product use, and in a final survey. all study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.

Eligibility criteria:
inclusion criteria: * adults, 21 years of age and older at the time of electronic consent, inclusive of all ethnicities, races, genders and/or gender identities * resides in the united states * endorses feelings of anxiety or stress as a primary issue (desire to reduce anxiety or less stress) * selects feelings of anxiety/stress, looking to improve their feelings of anxiety/stress, and/or reduce reliance on medications as a reason for their interest in taking a health and wellness product * expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study exclusion criteria: * pregnant, trying to become pregnant, or breastfeeding * unable to provide a valid physical shipping address * reports a diagnosis of liver or kidney disease * reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day) * unable to read and understand english * lack of reliable daily access to the internet * reports taking anticoagulants, any medication that warns against grapefruit consumption, corticosteroids at doses greater than 5 mgs per day, or maois (monoamine oxidase inhibitors) * reports current or recent (within 3 months) use of chemotherapy, immunotherapy, or oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection
safety, tolerance and efficacy of an oral nutritional supplement in lung cancer patients

Conditions: Cachexia; Cancer

Summary: to test the compliance, tolerance, safety and to get preliminary insights into the efficacy of a new oral nutritional supplement (containing n-3 fatty acids, amino acids and antioxidants) designed to prevent or delay cachexia and anorexia in lung cancer patients.


Eligibility criteria:
inclusion criteria: * non-small cell lung cancer patients stage iiib or iv * planned chemotherapy or combined chemo-/radiotherapy * current body weight less than 6 months ago * abnormal crf level * bmi \>=20 kg/m2 and \<=30kg/m2 exclusion criteria: * significant oedema in the time of screening and randomisation * concomitant inflammatory diseases * active infections including hiv and aids * liver failure * chronic renal failure or cardiac pacemaker * chronic heart failure * insulin treated diabetes mellitus * medications that impair sex hormone synthesis, secretion or function * acute or chronic infections * body weight loss \> 5% during the last 6 months or \> 10% during the last 10 months * fish oil supplementation within 3 months prior to study entry * taking vitamins in doses greater than recommended daily allowance * life expectancy less than 6 months in the opinion of the investigator
evaluation of eflornithine on facial and forearm skin

Conditions: Hirsutism

Summary: the purpose of this study is to evaluate whether regular use of eflornithine 11.5% cream in treating women with facial hair will induce skin damage (atrophy) on the face and/or forearms


Eligibility criteria:
inclusion criteria: * female subjects with clinical diagnosis of facial hirsutism/excessive facial hair * women of childbearing potential must agree to use an effective form of birth control for the duration of the study * skin type i-iv * customary frequency of removal of facial hair two or more times per week exclusion criteria: * pregnant or lactating women * severe inflammatory acne or presence of significant scarring on the face * history of skin malignancy * connective tissue disorders
safety and efficacy of tissue engineered endothelial keratoplasty

Conditions: Mild to Moderate Corneal Endothelial Decompensation; Bullous Keratopathy; Fuchs' Endothelial Dystrophy; Post-surgical Corneal Decompensation (Irreversible)

Summary: assessment of safety and efficacy of tissue-engineered corneal endothelial graft material generated using cultured human corneal endothelial cells for tissue-engineered endothelial keratoplasty (te-ek).

the specific aim of this clinical trial is to assess the clinical efficacy and safety outcomes of patients receiving tissue-engineered endothelial keratoplasty (te-ek) graft material generated from human corneal endothelial cells (hcencs) propagated in a regulatory-approved dual media approach. post-operative follow-ups and visits will follow current ek protocols of singapore national eye centre. clinical assessments include postoperative visual acuity, intraocular pressure, keratometric astigmatism, spherical equivalent, endothelial cell density, anterior segment optical coherence tomography (asoct), contrast sensitivity, as well as any postoperative complications such as graft dislocation or primary graft failure.

Eligibility criteria:
inclusion criteria: patients who have mild to moderate corneal endothelial decompensation or bullous keratopathy, but with minimal corneal stromal scarring resulting from a variety of conditions including: * fuchs' endothelial dystrophy * post-surgical corneal decompensation (irreversible) - all forms of pseudophakic or aphakic bullous keratopathy exclusion criteria: * severe forms or late stage presentation of corneal decompensation with severe corneal stromal scarring, unsuitable for te-ek surgery as opposed to penetrating keratoplasty * patients with complex anterior segment complications precluding a successful te-ek procedure * patients who have other forms of endothelial dystrophy, traumatic corneal decompensation, or post-inflammatory corneal decompensation * post-laser iridotomy or glaucoma related corneal decompensation * patients not keen to participate in the clinical trial * patients who are below 21 years of age or above 80 years of age * patients who are pregnant * patients who are cognitively impaired * patients who are prisoners * patients who are allergic to antibiotics